ZURICH, April 2 (Reuters) - Novartis took its campaign to invigorate sluggish sales of its new heart-failure medicine Entresto to a U.S. cardiologists meeting on Saturday, telling attendees that even clinically stable patients can benefit from the drug.
Read more
No comments:
Post a Comment